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Abstract
Proteomic analysis of myocardial tissue from patient population is suited to yield insights into cellular and molecular
mechanisms taking place in cardiovascular diseases. However, it has been limited by small sized biopsies and complicated
by high variances between patients. Therefore, there is a high demand for suitable model systems with the capability to
simulate ischemic and cardiotoxic effects in vitro, under defined conditions. In this context, we established an in vitro
ischemia/reperfusion cardiac disease model based on the contractile HL-1 cell line. To identify pathways involved in the
cellular alterations induced by ischemia and thereby defining disease-specific biomarkers and potential target structures for
new drug candidates we used fluorescence 2D-difference gel electrophoresis. By comparing spot density changes in
ischemic and reperfusion samples we detected several protein spots that were differentially abundant. Using MALDI-TOF/
TOF-MS and ESI-MS the proteins were identified and subsequently grouped by functionality. Most prominent were changes
in apoptosis signalling, cell structure and energy-metabolism. Alterations were confirmed by analysis of human biopsies
from patients with ischemic cardiomyopathy. With the establishment of our in vitro disease model for ischemia injury target
identification via proteomic research becomes independent from rare human material and will create new possibilities in
cardiac research.
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Introduction
Cardiac diseases and myocardial dysfunctions following ischemia
are the leading cause of mortality in western industrialized
countries. Ischemia and reperfusion injury, resulting from clinical
setting of coronary revascularization in acute myocardial infarction,
bypass surgery and heart transplantation is a demanding issue.
Many dysfunctions and defects have been described to be
responsible for the occurrence of ischemic injury; degeneration of
cytoskeleton [1], disturbances in calcium homeostasis [2], genera-
tion of reactive oxygen species [3], loss of high-energy phosphates
[4] and the occurrence of suicidal cell death [5,6] may play a crucial
role in pathogenesis. Treatment of myocardial infarction to restore
blood flow to the ischemic region by thrombolysis or coronary
artery bypass surgery leads either to hypoxic myocardial tissue,
where necrotic and wound-healing process is initiated [7] and
contractile function is lost; or blood flow through the myocardium is
re-established in time and tissue may regain its function, but may
also experience additional damage due to the reperfusion process
itself by generation of reactive oxygen species [8,9].
Proteomic studies of human disease derived pathological altered
tissue can provide new insights into the molecular mechanisms
that underlie the responses to ischemia and reperfusion injury.
These findings are important for drug development and could lead
to new approaches for novel therapeutic strategies. Two-
dimensional difference in gel electrophoresis (2D-DIGE) is a
potential tool for target identification, because fluorescence
labelling offers the possibility to separate and compare healthy
and diseased samples on one gel and analyse differences in a
quantitative manner by omitting gel to gel variances and a reliable
quantification [10].
Although human biopsy samples are the most suitable source of
material for identification of biomarkers and potential drug targets
in proteomic approaches, the size of individual samples is limited.
Another limitative aspect is the availability of well characterized
material that is normalized for the following criteria: disease state,
tissue heterogeneity, genetic variability, gender specificity, medical
history and therapeutic interventions [11]. Hence a model system
is needed, where pathological effects of ischemia and ischemia-
reperfusion could be properly simulated. To date a couple of
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infarction and ischemia-reperfusion in vivo and changes in their
myocardial proteomes were identified by 2D-gel electrophoresis
[12–16]. Here we describe the use of an in vitro model to
investigate effects of myocardial ischemia and ischemia-reperfu-
sion under controlled conditions. The mouse derived HL-1
cardiomyocyte cell line is the only cell line that can be passaged
indefinitely in culture while maintaining their contractile activity
and phenotypic characteristics of the adult cardiomyocyte in vitro.
HL-1 cells were intensively studied and characterized in terms of
cardiac morphological, biochemical and electrophysiological
properties. They show a high similarity in cardiac marker
expression of cardiac-specific myosin and muscle-specific desmin
intermediate filaments, syncytium formation as well as in
morphological and electrophysiological characteristics compared
to in vivo cardiomyocytes [17]. Because of these unique features,
HL-1 cells are the mean of choice for the in vitro simulation of heart
infarct, resulting in numerous studies that are described in the
literature including cultivation under hypoxic conditions [18],
nutrient deficiency [19] or oxidative stress [20].
The goal of the present study was to establish a HL-1
cardiomyocyte in vitro pathology model that recapitulates major
aspects of ischemia and ischemia-reperfusion injury and identify
changes in cardiac proteome as well as compare the results with
proteome data obtained from human biopsies to validate our
ischemic in vitro model system. With the help of these findings new
potential targets for drug discovery and drug development in
cardiac diseases could be identified.
Results
Establishment of an ischemic in vitro cell culture model
With the objective to develop an in vitro culture model for
cardiac ischemia, we established a disease model of using the
spontaneous contractile cardiac HL-1 cell line, were pathological
effects of ischemia and ischemia-reperfusion injury can be
simulated. For induction of ischemia in vitro, the standard used
Claycomb-medium was replaced by a nutrient deficiency medium
additionally contained 25 mM of hydrogen peroxide to enhance
the oxidative stress [21]. Microscopic investigations of ischemic
cell layers show a degeneration of the connected cell structure with
increasing incubation time in ischemic buffer (Fig. 1). Single cells
switched over to a stage of early cell death and detached from the
monolayer within the first hours of ischemia. Furthermore,
Figure 1. Analysis of ischemia induced changes in the cellular structure of HL-1 cardiomyocytes. While control and reperfused cells show
a vital cell layer consists of contractile HL-1 cardiomyocytes and an intact cytoskeleton structure, 8 h after ischemia-induction cells die off and
detached from the layer-assembly, indicated by reflecting microscopic structures. Furthermore contractility of HL-1 cardiomyocytes was stopped.
Immunocytochemical staining of this phase offered a degradation of the cytoskeleton filaments alpha-actinin, desmin and cadherin, which were
labelled with Cy
TM-antibodies (green). Nuclei were stained using SytoxH-orange. Scale bar microscopic images=25 mm, fluorescence images=50 mm.
doi:10.1371/journal.pone.0031669.g001
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ischemic HL-1 cultures using electrophysiological field potential
measurement (Fig. S1), whereas control cells showed no
interferences in monolayer structure and contractile behaviour.
To investigate effects caused by ischemia-reperfusion, a revitali-
zation period was initiated by medium exchange with standard
Claycomb-medium and cells retained for 16 h. After revitalization
time cell culture display a regeneration of aggrieved cells by the
rebuild of a complex monolayer. In addition, we observed a
revival of cardiac contraction.
2D DIGE analyses of ischemic and ischemia-reperfused in
vitro cultures
Changes in protein expression profile after 8 h of induced
ischemia and after 16 h of ischemia-reperfusion were analysed
using the DIGE 2-DE approaches (Fig. 2). We detected 1435
protein spots in the ischemic HL-1 proteome by 2-DE and
quantified the expression of ischemic HL-1 cells with pI between 3
and 10 using Delta 2D software, version 3.6, yielding 644 spots
displaying a difference in protein expression stronger than 2-fold
(p,0.05). In general, we detected more repressed (441) than
induced protein spots (203) after 8 h incubation in ischemic buffer
(Fig. 2A). Comparison between ischemic samples and controls
showed a clear clustered Heatmap according to the experiments
and a high similarity between the three independent replicates
(Fig. S2). By using an unsupervised approach comprising all spots
the gels were clustered into the correct groups. Changes in
expression profile after revitalization in comparison to the control
were reduced to a minimum, indicating a regeneration of HL-1
cells during re-incubation in Claycomb-medium and an approx-
imation to the control state (Fig. 2B). Alike expression profile of
8 h samples, we detected more repressed than induced protein
spots in revitalized HL-1 cardiomyocytes. By tryptic digest and
MS analysis of the peptides in order to create a proteome map of
HL-1 cells, we identified 81 differentially expressed proteins from
ischemic HL-1 cells (Table S2) and 14 protein spots, which were
differentially expressed after reperfusion-time using MALDI-MS
(Table S3). In detail, identified proteins are involved in cell death
signalling (death associated protein kinase 2, granzyme K),
oxidative stress regulation (stress induced phosphoproteine 1),
protein quality control (HSPA2), cell structure organisation or
metabolism related proteins (Fig. 2C, Table 1).
Validation of the 2-DE results
From each of the four biological pathways, apoptosis, molecular
chaperons, cell structure proteins and cell metabolism, we have
initially chosen two representative proteins to validate 2-DE results
by an independent method. Using SDS-PAGE and immunoblot
Figure 2. Proteome changes in HL-1 cardiomyocyte cell line with induction of ischemic conditions and after reperfusion. In total
360 mg of cytosolic proteins of ischemia-induced HL-1 cells (A) and reperfused HL-1 cells (B) were separated by DIGE-2-DE (18 cm IPG stripes 3–10
non-linear, 10% acrylamide/bisacrylamide). C) Gel image regions of differentially expressed proteins following ischemia induction. Abbreviations are
gene names. The details of identifications are shown in Table S1 and Table S2.
doi:10.1371/journal.pone.0031669.g002
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in HL-1 cardiomyocytes.
ID
a Protein involved in process Accession
b Fold change
c
gel1 gel2 gel3 fusion
Cell death signaling/
apoptosis
12 Annexin A5 P48036 1.972 0.436 0.741 1.049
6 Vinculin Q64727 1.982 1.547 2.049 1.848*
78 Granzyme K Q9R0K0 7.800 - 7.254 7.527
71 Death associated protein kinase 2 Q9UIK4 - 7.949 7.543 7.746***
2 Tyrosin-3/tryptophan-5-monooxygenase P62259 0.380 0.173 0.321 0.291
13 Protein kinase C inhibitor protein 1, 14-3-3-zeta P61101 3.408 3.675 2.810 3.298
49 Eukaryotic translation initiation factor 4A Q91VC3 0.510 0.533 0.769 0.604
58 Nucleoside diphosphate kinase 2 Q01768 4.706 5.454 6.271 5.477
61 Serpin h1 (Ser/Cys Proteinase Inhibitor) (HSP47) Q5U4D0 0.098 0.522 0.170 0.263
67 Lamin B1 Q61791 0.388 0.556 0.545 0.496**
63 Nucleophosmin 1 Q61937 0.320 0.567 0.459 0.449**
Oxidative stress
1 Peroxyredoxin 3 P30048 1.267 1.184 - 1.227
44 Aldehyde dehydrogenase 2, mitochondrial P47738 0.399 0.615 0.545 0.519*
70 Stress induced phosphoprotein Q60864 2.108 2.147 - 2.158*
31 Valosin containing protein Q01853 2.900 1.606 1.632 1.956**
46 Selenuim binding protein P17563 5.898 2.061 3.165 3.708**
75 NADH-dehydrogenase (ubiquinone) 1-beta Q9CR21 3.121 2.230 1.974 2.442
55 Phosphoglyceratmutase Q9DBJ1 1.823 1.955 1.581 1.786
Protein quality control
10 Heat shock protein 90 - beta (HSP 84) P11499 0.342 0.051 0.037 0.143
11 Heat shock protein 90 - alpha (HSP 86) P46633 0.220 - 0.037 0.129
63 Nucleophosmin 1 Q61937 0.320 0.567 0.459 0.449**
30 Heat shock protein 1 P11499 1.532 1.996 1.752 1.760
32 Heat shock protein 9 P38647 0.377 0.223 0.241 0.280
34 Heat shock protein 65 P63038 4.770 7.147 4.229 5.382***
45 Chaperonin 2 (beta) (HSPA2) P80314 5.825 2.649 3.413 3.962**
61 Serpin h1 (Ser/Cys proteinase inhibitor) (HSP47) Q5U4D0 0.098 0.522 0.170 0.263
59 Peptidyl-prolyl-cis-trans isomerase P17742 4.668 - - 4.668
Cell structure proteins
65 Destrin Q9R0P5 6.379 - - 6.379
35 put. beta-actin P60710 4.535 - 3.131 3.833*
22 Vimentin P20152 0.007 0.020 0.759 0.262*
73 Desmin P31001 0.062 0.028 0.092 0.061
28 Tubulin beta 5 P99024 2.086 - 1.674 1.880
67 Lamin B1 Q61791 0.388 0.556 0.545 0.496**
Energy metabolism
26 Phosphoglycerate kinase 1 P09411 3.535 7.459 1.422 4.139***
37 Ubiquinol-cytochrom-c reductase core protein 1 Q9CZ13 0.634 0.335 0.926 0.632
47 Enolase 3, beta muscle P13929 8.671 6.014 5.691 6.792*
54 Lactat dehydrogenase A P06151 12.153 6.044 8.854 9.017**
48 Pyruvate kinase M P52480
55 Phosphoglyceratmutase 1 Q9DBJ1 1.823 1.955 1.581 1.786
56 Malat dehydrogenase, cytoplasm P14152 7.549 7.815 3.969 6.444**
57 Triosephosphate isomerase (TIM) P17751 9.144 6.492 9.204 8.280
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induction in HL-1 cardiomyocytes, we were able to confirm the
results from 2-DE (Fig. 3). By analysing the caspase-3 substrate
PARP, which is cleaved in a consequence of apoptotic cascade
activation, we could distinguish an increase of cleaved-PARP in
ischemic HL-1 cardiomyocytes eight hours after ischemia
induction (5-fold) indicating that apoptosis plays a crucial role in
ischemia, although revitalization leads to a decrease of cleaved-
PARP in ischemic HL-1 cardiomyocytes. Also HSP70 and HSP90
expression correlates with the data observed from 2-DE. Whereas
ischemic cells showed a slightly but not significant increase of
HSP90 expression from 51.661.4% (control) compared to
58.067.6% (ischemia) after eight hours HSP70 decreased
significantly from 10.460.2% (control) compared to 8.560.2%
(ischemia). However, both heat shock proteins showed a significant
decrease after reperfusion. The specific detection of decreasing
connexin-43 pointed to a degradation of the cell-cell contacts and
the cytoskeleton (7-fold down-regulated). Other cytoskeleton
proteins, like beta-actin and desmin, were shown to be also
down-regulated in the 2-DE. Finally, we were also able to
demonstrate the activation of catabolic energy processes, like
glycolysis enzymes, as a result of ischemia injury. Complete values
are shown in Table S3.
Effects of induced ischemia on cellular structure in the
HL-1 cell monolayer
For further validation of 2-DE and western blot data, the
expression and subcellular organization of the molecular maker
proteins alpha-actinin, desmin and cadherin were investigated by
immunocytochemical staining (Fig. 1). In control cells filaments and
structural proteins were expressed constantly during the whole
experiment, whereas ischemic HL-1 shows destruction in that,
resulting in a cessation of contractility. The actin-crosslinking
protein alpha-actinin is diminished in cardiomyocytes 8 h after
ischemia induction. This effect is corrected after revitalization,
where the expression of alpha-actinin occurs increased. Same effect
could be observed in the immunocytochemical analysis of the
intermediate filament desmin. Following 8 h incubation of HL-1
cardiomyocytes in ischemic buffer, desmin expression is decreased,
whereas desmin level increases after revitalization period in
Claycomb-medium. This cytoskeleton degradation indicates the
reduction of contractility behaviours during ischemia, whereas
rebuilding of cytoskeleton organisation after revitalization period
recovering cardiomyocytes contractility. Beside this, observed
shrinking of nuclei indicated the cell degradation during apoptosis.
Furthermore we could demonstrate a loss of cell-cell interactions
in HL-1 cardiomyocytes in consequence of ischemia and apoptosis
by immunocytochemical staining of the cell-connecting trans-
membrane protein cadherin. Cadherin expression in the cell-cell-
interspaces of control samples specifies a well-connected cell layer.
In contrast to that incubation in ischemic buffer led to a down
regulation of cadherin, and disturbed contraction forwarding may
be due to the resulting syncytium failure. However, cadherin
expression and the formation of a large-area contractile monolayer
recovered after revitalization.
Effects of induced ischemia on proliferation and
apoptosis in HL-1 cells
Due to the fact, that ischemia and reperfusion time is strongly
associated with apoptosis and changes in proliferation behaviours,
treatedHL-1 cells were analysed using TUNEL-apoptosisassay and
Click-iT
TM proliferation assay.Themean valuesand standard error
of mean of three independent experiments were calculated for both
applications and statistically analysed for significance (Fig. 4).
Flow cytometry analysis showed a significant increase of
apoptotic cells after induction of ischemia; confirm the data from
2-DE and western blot analysis. While non-treated cells showed a
considerably low percentage of apoptotic cells within the whole
experiment (1.1660.31% and 2.0360.44%), incubation of HL-1
cells in nutrient deficiency medium led to an increase of apoptosis
rate to 14.6861.5% after 8 h. Even 16 h after revitalization in
standard Claycomb-medium, the number of apoptotic cells were
still significantly higher (5.0760.62%) compared to control
samples.
Proliferation analysis was done using the incorporation of 59-
ethynyl-29-desoxyuridine (EdU) in genetic material during active
DNA-synthesis. Due to different incubation times with EdU
caused by the experimental protocol, all results have to be
normalized to respective control values. However, incubation of
HL-1 cells under ischemic condition led to a significantly decrease
of relative proliferation to 65.61614.26%, whereas revitalization
of ischemic HL-1 cells in standard Claycomb-medium results in a
mercurial increase of relative proliferation rate up to 117.768.5%
indicating a nearly complete revitalization of ischemic cells.
ID
a Protein involved in process Accession
b Fold change
c
gel1 gel2 gel3 fusion
64 Glycerinaldehyde-3-phosphate dehydrogenase P16858 7.419 6.152 12.700 8.757***
77 Fructose-bisphosphate-aldolase 1 P05064 7.802 5.373 2.973 5.383**
3 Succinate dehydrogenase Fp subunit Q8K2B3 0.471 0.376 0.548 0.465*
7 Alpha-glycosidase 2 alpha neutral subunit Q8BHN3 0.487 0.439 0.486 0.471***
8 Aconitase 2, mitochondrial Q99KI0 0.585 0.375 0.187 0.382
43 Dihydrolipoamide S-succinyltransferase Q9D2G2 0.383 0.604 0.748 0.578
51 3-oxoacid CoA transferase 1 Q9D0K2 0.575 0.307 0.334 0.405
Inflammation
9 Complement component 1, q subcomp. binding protein Q8R5L1 1.565 1.679 1.020 1.421
a) Spot ID from Fig. 2A.
b) Swiss-Prot accession.
c) Fold change (exposed versus control) following induction of ischemia (n=3, *p,0.05, **p,0.01 and ***p,0.001).
doi:10.1371/journal.pone.0031669.t001
Table 1. Cont.
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following ischemic cardiomyopathy
First experiments to analyse human proteome from patients
with ischemic cardiomyopathies by DIGE 2-DE showed a high
concentration of human serum albumin, which interfered with the
adequate focusing and detection of lower abundance proteins (Fig.
S3). Potential protein biomarkers are supposed to occur at
concentrations up to 10 orders of magnitude less than the most
abundant proteins. For biomarker discovery and subsequent
biomarker evaluation it is essential to reduce the dynamic range
Figure 3. Cytosolic HL-1 cardiomyocyte proteins showing changes in expression after cellular exposure to ischemic conditions. (A)
For four identified pathways verification was done by western blot analysis of two proteins per pathway. Shown is the expression in HL-1
cardiomyocytes after induction of ischemia (8 h) and after reperfusion (24 h) from control (C) and treated cells (I). (B) All protein expression levels
were calculated relative to the housekeeping protein histone H3 and three to six experiments were statistical analysed.
doi:10.1371/journal.pone.0031669.g003
Figure 4. Apoptosis and proliferation analysis of ischemic HL-1 cardiomyocytes. Induced ischemia resulted in an increased apoptosis and
decrease of proliferation. (A) For quantification apoptotic cells were stained using the TUNEL-assay, proliferating cells were labelled with EdU using
the Click-iT
TM-assay and analysed via flow cytometer. For comparison of different time points, proliferation values were normalized to controls of the
corresponding time point (n=3). (B) Immunocytochemical staining of TUNEL positive apoptotic HL-1 cardiomyocytes (red) and EdU positive
proliferating cells (green) in control cells, ischemic cells and reperfused cells. Total cell number obtained by a DAPI stain (blue). Scale bar=100 mm.
doi:10.1371/journal.pone.0031669.g004
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based depletion of high-abundant proteins has been described as
the most specific method for removal of highly abundant proteins
[24] and may increase the detection of the lower abundance
proteins which otherwise would not be visible.
With the objection to reduce the complexity of biopsy proteome
for subsequent proteomic 2-DE DIGE analysis we depleted high
abundant albumin and IgG using monoclonal antibody strategy
according to manufacturer’s instruction (Qiagen). Following
removal, samples were subjected to SDS-PAGE as a preliminary
screen for efficacy and specificity of removal method, exposing
almost complete depletion. Removal columns were essentially
devoid of albumin and IgG and the albumin fractions contained
predominantly the albumin line (Fig. S3A). To assess depletion
rates Coomassie-stained gels were analysed using densitometry.
Depletion averages at least 79.27610.19%.
The depletion of the high-abundant proteins albumin and IgG
from human biopsy samples allowed the loading of 450 mg
protein of the enriched fraction and thereby the detection of
spots previously masked by high-abundance proteins in terms of
mass and spot size. Especially albumin covered a large area on 2-
DE gels of crude samples that could be used for resolving other
spots after depletion. With the sample complexity reduced, and
the detection range increased (Fig. S3B), we turned our efforts for
protein identification in male and female human samples.
Typically 2-DE spot patterns of male and female biopsies are
shown in Fig. 5. For quantitative analysis digitalized fusion gel
was composed of a total of three gels in with the Cy 5-labeled
ischemia samples were compared to the Cy 3-labeled controls. In
total 739 protein spots could be detected in the male fusion gel,
and 962 spots were detected in the female fusion gel. We
quantified the expression using Delta 2D software, version 3.6. In
male 2-DE gels 171 protein spots (that equates 22.8% of all
detected spots), in female 2-DE gels 341 spots (35.8%) displayed
a difference in expression stronger than 2-fold with p,0.05,
appeared in all of the three gel-replicates. The reproducibility of
the 2-DE gels was confirmed by hierarchical cluster analysis. The
comparison between the diseased and control samples showed a
clear clustering of the gels according to the groups of samples
(heatmaps are shown in Fig. S2). We investigated 60 of these
spots per gender by tryptic digestion and MS analysis of the
peptides. Finally, we could identify 53 male and 56 female
significantly regulated spots using ESI-MS. Following ischemia
injury 14 protein spots were up-regulated and 33 spots were
down-regulated in male samples, 16 protein spots were up-
regulated and 40 spots were down-regulated in female samples.
Proteins could be classified in different cellular processes such as
oxidative stress regulation, cell death signaling, inflammation,
cytoskeleton organisation, protein quality control and metabo-
lism (Table 2; all identified proteins were listed in Table S4 and
Table S5).
Findings are in good agreement with the identified proteome
data collected from in vitro HL-1 disease model. Proteins could be
clustered into the same groups (Table 1 and Table 2), demon-
stration the suitability of our in vitro model system for simulating
ischemic effects.
For validation of the biopsy proteome data, we analysed the
heat shock proteins HSP70 and HSP90 by western blot analysis,
which were significant differentially expressed in 2D-gels. Whereas
HSP90 variants showed a decrease in diseased male and female
samples (ratio of 0.75 and 0.15/0.2) the HSP70 protein 8 isoform
1 was up-regulated (ratio 6.58) in male, but down-regulated (ratio
0.49) in female samples. Same trend was observed in western blot
analysis (Fig. 6B). Both gender showed a decrease of HSP90 level
after ischemia injury with a ratio of 0.2 in male and 0.03 in female
samples, but a different attitude in HSP70 expression. Whereas in
male biopsy samples the HSP70 level increased up to the 15-fold
of magnitude, HSP70 expression in female samples decreased to a
ratio of 0.8. These data are in good agreement with the proteome
data of heat shock protein 70 and 90.
Figure 5. Proteome map of human biopsy samples from patients with ischemic cardiomyopathy. (Identification data are shown in Table
S4 and Table S5). In total 360 mg protein of male (A) and female (B) biopsy samples were separated by DIGE-2-DE (18 cm IPG stripes 3–10 non-linear,
10% acrylamide/bisacrylamide).
doi:10.1371/journal.pone.0031669.g005
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ID
a
Protein involved in process Gender Accession
b Fold change
c
male/female male female
Cell death signaling/apoptosis
34/43 Annexin A5 male/female gi|809185 67.74** 0.12*
1 Serpin peptidase inhibitor, clade A female gi|15990507 - 0.06*
35 Tyr3/trp5 -monooxygenase activation protein, epsilon male gi|5803225 2.59 -
25 Cullin 1 female giI21358757 - 0.12**
33 Rho GTPase activating protein 21 female giI57162515 - 0.11**
40 EDAR-associated death domain, isoform CRA_b female giI119590454 - 5.86
56 Inhibitor of apoptosis protein1 female giI110590599 - 0.15**
58 Apoptosis-inducing factor (AIF) female gi|14318424 - 0.21*
37 Chain A, 14-3-3 Protein Epsilon female gi|67464424 - 0.29
Oxidative stress
44 Mit. aldehyde dehydrogenase 2 precursor variant male gi|62898307 122.34 -
40 Carbonic anhydrase I male gi|4502517 2.56 -
Protein quality control
19/13,14 Heat shock 70 kDa protein 8 isoform 1 male/female gi|5729877 6.58* 0.49*
21/3 Heat shock protein 90 kDa beta, member 1 male/female gi|4507677 0.75 0.15
50 Heat shock protein beta-1 (=HSP27) male gi|4504517 1.76 -
8 Heat shock protein HSP 90-alpha 2 female gi|61656603 - 0.20
10 Heat shock 70 kDa protein 5 female gi|16507237 - 0.75
46 Mitochondrial heat shock 60 kD protein 1 variant 1 female gi|189502784 - 0.25
34 Peptidylprolyl isomerase E (Cyclophilin E) female giI62955333 - 0.10*
28 Calreticulin precursor male gi|4757900 0.20* -
Cell structure proteins
49 Beta actin variant female gi|194385944 - 0.25**
52 Tropomyosin beta, isoform 2 female gi|47519616 - 76.21
33/5,26,54 Tropomyosin alpha, isoform 1 male/female gi|49660014 596.89 34.92
53 Tropomyosin alpha, isoform 2 female gi|63252902 - 292.74
27 Troponin T female gi|408217 - 43.09
38 Tropomyosin 4, isoform 2 female gi|4507651 - 0.91
39 Tropomyosin 3, isoform 2 female gi|24119203 - 4.40**
11 Intermediate filament protein female gi|28317 - 0.36*
Inflammation
24,25,58/59 Transferrin male/female gi|4557871 0.31 0.69
5/22 Complement factor B male/female gi|291922 0.04* 1.79
8/19 Ceruloplasmin (ferroxidase) male/female giI11999289 0.06* 0.83
16/16 Complement factor H male/female gi|62739186 0.10 0.53
1 Alpha-1-antichymotrypsin male gi|177809 0.18* -
9 Coagulation factor II preproprotein female gi|4503635 - 0.25*
23 C9 complement protein male gi|179726 0.32 -
Energy metabolism
3 Gelsolin isoform a precursor male gi|4504165 0.10 -
14,15 Aconitase 2 male gi|4501867 0.07* -
29,30/28,29 Mit. ATP synthase, H+ transporting F1 complex beta male/female gi|89574029 1001.29 29.91*
42 Triosephosphate isomerase male gi|999892 10.56 -
44 Mit. aldehyde dehydrogenase 2 precursor variant male gi|62898307 122.34 -
45 Cytosolic malate dehydrogenase male gi|5174539 0.80 -
35 2-phosphopyruvate-hydratase alpha-enolase female gi|693933 - 0.04*
47 Creatine kinase B male gi|180555 0.09* -
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Heart disease is the leading cause of mortality and morbidity in
the world [25] and presently the most costly health care diagnosis.
Due to the lack of effective tools, most early stage of heart disease
is not detected clinically until irreversible tissue damage accrues,
therefore the discovery of biomarkers allowing for early diagnosis
and therapeutic monitoring of at risk patients is urgently needed.
Proteomics is a powerful tool for biomarker discovery as well as
target identification for novel drug design [11], because changes in
global protein expression levels of cardiomyocytes in response to
ischemic conditions may provide unique insight and understand-
ing of the respective underlying mechanisms. Although the most
suited medium for that would be blood samples it seems advisable
to understand in more detail the changes in the affected tissue
prior to tedious serum screening.
Proteomic studies of human heart tissue are complicated by
factors such as disease state, tissue heterogeneity, genetic
variability, medical history and therapeutic investigations [11].
To overcome these problems many animal models of ischemic
disease have been established. With this work our aim was to
develop a mouse myocardial infarction in vitro model to study
cellular and molecular changes after induction of ischemia and
ischemia/reperfusion, without any artificial influences of animal
models like genetic diversity or retrovirus infection [26]. Therefore
we applied the contractile cardiomyocyte cell line HL-1, which is
the only cell line that contracts and maintains phenotypic and
electrophysiological characteristics [17]. Due to the extensive
changes caused by the induction of ischemic conditions also the
abundances of proteins was altered rather dramatically. In general,
more repressed than induced protein spots were identified in
ischemic HL-1 cells, in which mainly degradation processes were
involved, like decomposition of cytoskeletal proteins or cell-cell
contact proteins. This reorganization was also detected by
immunocytochemical staining of alpha-actinin, desmin and the
cell-adhesion molecule cadherin (Fig. 1). 8 h after induction of
ischemia degradation of cytoskeleton and a loss of cell-cell contact
by degradation of the cell monolayer could be detected, what
affects a cessation of contractile behaviours in HL-1 cells. The
observed loss of contraction power and frequency was monitored
via microscope and field potential measurement (Fig. S1) and was
in concordance with former in vivo and in vitro studies [27].
Additionally, ischemia causes a lack of energy. For example, in the
ischemic heart, a reduction in mitochondrial oxidative capacity
serves to reduce oxygen consumption in the context of limited O2
availability. Reduced capacity for energy transduction leads to
deregulation of cellular processes critical for cardiac pump
function, including Ca
2+ handling and contractile function
[15,28]. In the ischemic state many proteins involved in glycolysis
were increased, whereas proteins involved in energy consuming
pathways were decreased, pointing to a counteractive mechanism.
This finding is in agreement with previous studies [29]. Moreover,
proteins which reveal an induction of apoptosis in cellular response
due to ischemia conditions were detected. In this context, early
apoptosis promoting mechanisms were found to be activated.
Vinculin, granzyme k and annexin A5 were up-regulated, whereas
nucleophosmin 1, a protein that prevents apoptosis [30,31] and
inhibit the caspase-activated DNase [32] was down-regulated in all
three replicates. Immunocytochemical staining of the cytoskeleton
components (Fig. 1) showed also shrunken nuclei, indicating
a) Spot ID from Fig. 2A.
b) NCBI accession.
c) Fold change (exposed versus control) following induction of ischemia (n=3, *p,0.05 and **p,0.01).
doi:10.1371/journal.pone.0031669.t002
Table 2. Cont.
Figure 6. Gel image regions of differentially expressed proteins following ischemic cardiomyopathy in male and female biopsies.
(A) Abbreviations are gene names. Regions are emphasized in the DIGE-2D-gel images in Figure 5. (B) Relative Expression of HSP70 (left) and HSP90
(right) in male and female biopsies by western blot analysis, normalized to control samples.
doi:10.1371/journal.pone.0031669.g006
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analysis revealed an increase of apoptosis by ischemia induction,
too. These findings are in line with earlier studies that showed an
increased apoptosis rate in cardiomyocytes in consequence of
myocardial infarction [33,34]. Furthermore, the observed decrease
of proliferation is prominent in cardiac infarct and its implications.
However, by induction of reperfusion in HL-1 cardiomyocytes
using Claycomb-culture medium cells increased proliferation
behaviours, displaying regeneration in cell vitality. After reperfu-
sion phase proteome alterations approximate to control samples.
There were significantly less changes in reperfused than in
ischemic 2DE-gels. Mostly, proteins involved in cell death signals
or oxidative stress regulation were detected, what is in accordance
with former studies of cardiac remodelling after acute myocardial
infarction [15,35].
To validate the results of our HL-1 disease model human biopsy
samples, collected from patients with ischemic cardiomyopathy
were analysed via 2D-GE and compared to the ischemic in vitro
samples.
One major challenge in functional proteomics is the
separation of complex samples prior to comparative analysis
e.g. for disease marker identification. This applies especially for
blood samples but was also found to happen in case of the biopsy
samples from heart tissue. For this reason we applied the
depletion of the high abundant serum proteins albumin and IgG
using the Depletion kit from Qiagen and achieved a diminution
of 79.27610.19%, increasing the detection of the lower
abundance cytosolic proteins which otherwise would not have
been visible. Thus we were able to identify changes in the
proteome from male and female patients with ischemic
cardiomyopathy. Identified proteins agreed with published
proteome data taken from human DCM (dilated cardiomyop-
athy) and ischemic animal models [11]. Standard two-dimen-
sional gels can routinely separate 1,000 to 2,000 proteins from a
total cardiac extract [36]. However, it is clear that this gives
incomplete proteomic coverage for the human heart, which may
express more than 10,000 proteins [11]. Nonetheless, we
detected cytoplasmatic proteins, which are involved in relevant
pathological processes. Troponin T has been demonstrates as
most reliable to detect and estimate the extent of cardiac damage
[37]. Apolipoprotein E, tropomyosins, alpha-2 macroglobulin,
complement 3, creatin kinase B and ceruloplasmin have been
also described as biomarkers for chronic heart failure [38–42].
Comparing the identified proteins from the biopsy material with
the in vitro model, we are aware that a 24 hour in vitro model
never could be completely comparable to a pathological in vivo
situation that arises over years or even decades. So the aim of
our study was first to identify the main altered pathways, not
single proteins in our 24 hour in vitro ischemic cardiomyopathy
model and second to validate it with ischemic cardiomyopathy
biopsies from patients. Therefore, we could demonstrate a
correlation of identified pathway alterations. So we are
absolutely convinced that our developed and analyzed in vitro
model could be useful to overcome the dilemma of the research
community and especially of the pharmaceutical industry, where
easy to handle standardized culture models with fast developing
pathology are needed (e.g. for the active pharmaceutical
ingredients development).
Furthermore, we were able to demonstrate a differential protein
expression pattern from male and female proteome of patients
with ischemic cardiomyopathy. Thus a gender specific expression
of HSP70 was observed in human biopsy samples. Whereas in
male proteome HSP70 was significant up-regulated, HSP70 was
down-regulated in female samples (Fig. 6A). This finding is of great
importance showing that for individual therapy target a gender
specific treatment have to be taken into account. Beside this
gender specific single protein expression differences, in general our
investigation of male and female biopsies revealed common
alterations in the biological pathways, such as oxidative stress
mechanisms, apoptosis and cell death, cytoskeletal reorganization,
energy metabolism and Ca
2+-homeostasis as identified by database
search and peer reviewed journal screening.
In addition to the identified proteins with altered expression
post-translational modifications (PTMs) are important for the
regulation of functional activities of proteins. PTMs such as
phosphorylation or acetylation could be identified in the imaged 2-
DE gels as ‘‘train of spots’’.
Unfortunately, the search for phosphorylation and acetylation
on the basis of the obtained spectra we could not unambiguously
identify any of those PTMs. Since PTMs were not the main
intension of this study, we didn’t investigated in PTMs by further
experiments. But having now a validated in vitro ischemia model
we can use it now for further studies also with regard to PTMs.
Conclusion
Demonstrating the suitability of our mouse myocardial
infarction model for studying cellular and molecular changes after
induction of ischemia and ischemia-reperfusion in vitro we were
able to illustrate similar alterations in the proteome as seen in
pathological biopsies taken from patients with ischemic cardiomy-
opathy concerning proteins of cell death pathways and oxidative
stress response. Our in vitro model opens up the path to investigate
cellular mechanisms that are involved in ischemia and cardiac
dysfunctions recapitulating major pathway alterations close to the
in vivo situation and thereby offers the chance to identify new
diagnostic and therapeutic markers.
Materials and Methods
Ethics Statement
The collection of human cardiac tissue samples used in this
study was approved by the Ethics Committee of the Medical
University of Vienna, and individuals who signed the written
informed consent to be enrolled were included between January
2004 and July 2008.
Cell culture and induction of ischemia in vitro
The HL-1 cardiomyocytes (murine atrial tumor cell line) were
maintained in monolayer culture with Claycomb-medium (Sigma,
Germany), supplemented with 10% fetal calf serum (SAFC-
Biosciences, USA), 1% penicillin/streptomycin, 1% glutamax
(both Invitrogen, Germany) and 1% norepinephrine (Sigma-
Aldrich, Germany) in an incubator containing 5% CO2 at a
relative humidity of 95% and 37uC. 8610
5 cells/cm
2 were seeded
in supplemented Claycomb-medium on fibronectin/gelatine-pre-
coated cell culture flasks. Coating was performed using a 1 mg/ml
fibronectin-solution in 0.02% gelatine (Sigma-Aldrich, Germany)
and incubate at 37uC overnight. The Claycomb-medium, which is
specifically designed for the growth of HL-1 cells, was replaced
approximately every 48 h. Heaving reached confluence and
contractile activity, cells were maintained as subcultures using
0.05% trypsin/EDTA (Invitrogen, Germany) and subsequently
incubated under standard culture conditions.
Induction of ischemia was carried out on vital cardiomyocytes at
culture day four. The subconfluent, contractile HL-1 cardiomy-
ocytes were placed in nutrient-deficiency medium (136 mM NaCl,
5.4 mM KCl, 1 mM CaCl2, 0.53 mM MgCl2 and 5.5 mM
HEPES in aqua dest., pH 6.7), containing 2.5 mM hydrogen
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oxidative stress in HL-1 cells. In control cultures the medium
exchange was carried out with standard supplemented Claycomb-
medium. 8 h after ischemia induction samples were harvested and
revitalization was induced in parallel by replacing nutrient-
deficiency medium with fresh Claycomb-medium and incubating
cells for another 16 hours.
Immunocytochemistry
For indirect immunofluorescence, HL-1 cells were grown on
fibronectin/gelatine-coated glass coverslips, harvested at appro-
priate culture stages, and fixed with 4% formaldehyde in
phosphate buffered saline for 15 min at room temperature. After
repeated washing and dehydration, glass coverslips were stored at
220uC until use.
For immuncytochemical staining frozen glass coverslips were
dried for 15 min at 37uC on a hotplate. Then cells were
permeabilised by incubation with 3% BSA/0.1% Triton X-100
in PBS for 45 min at room temperature. The primary antibodies
used for immunofluorescent staining were: monoclonal mouse-
anti-a-actinin (Sigma- Aldrich, Germany) in a dilution of 1:500,
polyclonal rabbit-anti-desmin (1:100; Dianova, Germany) and
monoclonal mouse-anti-cadherin (1:100; Abcam, UK). The
secondary antibody was either Cy2-conjugated goat-anti-mouse
IgG- or goat-anti-rabbit IgG. Nuclei were stained with SytoxH-
orange (1 mM, Invitrogen, Germany).
The cultures were examined using a Nikon TE2000 fluores-
cence microscope equipped with a confocal laser scanning unit
and documented with the EZ-C1 software.
Proliferation and apoptosis assay
Cell proliferation analysis was done by flow cytometry via Click-
iT
TM-EdU assay as described in detail in the manufacturer’s
instruction (Invitrogen). For labeling cells with EdU (5-ethynyl-29-
desoxyuridine, Invitrogen/Karlsruhe) the nucleoside analogue was
added to the medium in a final concentration of 10 mM 8 h and
accordingly 16 h before harvesting treated and non-treated HL-1
cells. Apoptosis analysis was performed by terminal desoxynu-
cleotidyl transferase-mediated dUTP nick end-labeling using the
Click-iT
TM TUNEL Alexa Fluor-488 assay (Invitrogen). Ischemic/
reperfused and non-ischemic cells were collected using 0.25%
trypsin/EDTA and fixed in 4% formaldehyde solution for 30 min
at room temperature. Afterwards cells were kept in 0.1% triton/
PBS until cell staining and flow cytometry with the FACS analyser
FACS-Calibur (BD Biosciences, USA). Total number of cells was
determined using 7-AAD nucleus staining (0.05 mg/ml; BD
Biosciences, USA).
Additionally formaldehyde-fixed cells on glass coverslips were
prepared for immuncytochemical staining as described in section
2.2. TUNEL assay was performed using the In Situ Cell Death
Detection Kit TMRred (Roche Diagnostics, Mannheim/Germany),
whereas Proliferation behaviour was analysed via Click-iT
TM-EdU
assay (Invitrogen). Nuclei were stained with DAPI (0.1 mg/ml,
Sigma-Aldrich) to detect the total number of cells. Cultures were
examined and documented with a Nikon Eclipse 200 fluorescence
microscope with the LUCIA 4.8 software.
Human myocardial samples and protein isolation
Human biopsy materials were received as protein lysates from
University hospital of Vienna. The myocardial biopsies were
collected from explanted hearts ofp a t i e n t s( 3m a l e s ,3f e m a l e s ,
age 44–61 years) with ischemic cardiomyopathy (ICM) under-
going cardiac transplantation according to the American Heart
Association criteria as referredt oe a r l i e r[ 4 3 ] .T h ec o n t r o l
group consisted of 6 heart donors (3 males, 3 females, age 31–47
years old) with no history of cardiac disease whose hearts could
not be transplanted due to quality reasons. The inclusion and
exclusion criteria of patients have been performed as described
[44]. All patients underwent an optimized heart failure
treatment prior to transplant, including angiotensin-converting
enzyme inhibitors, angiotensin II receptor blockers, beta
b l o c k e r s ,s t a t i n s ,s e d a c o r o n ,d i g i t a l i s ,c o u m a r i na n dp r o s t a g l a n -
din. After obtaining informed consent, myocardial biopsies were
dissected 20 mm distal to the diagonal branch and 20 mm from
the left anterior descending coronary artery from the left
ventricle of the explanted hearts as described elsewhere [45].
Samples were coded, snap frozen and stored in liquid nitrogen
until further use.
For protein isolation the myocardial biopsies were homogenized
in Flackelton Lysis buffer, containing PMSF (1 mM), Na3VO4
(100 mM) and EDTA-free protease inhibitor cocktail (4%, Roche)
and the cytosolic fraction of protein extracts was stored at 280uC.
Albumin and IgG depletion in human protein samples
Serum albumin and IgG were depleted from protein samples
by applying the Albumin and IgG Depletion Kit Qproteome
TM
(Qiagen, Germany) using immunoaffinity-based depletion spin
columns. Control protein samples were mixed 1:1, ischemic
biopsy samples 9:1 with 20 mM HEPES buffer (Merck; pH 7.2),
and applied onto the pre-equilibrated columns. Columns were
shaken vigorously to obtain a homogenous suspension and
incubated for 5 min on an end-over-end shaker at room
temperature. Flow through, containing the depleted protein
sample, was collected by centrifugation at 5006g for 10 s. After
washing columns with 26100 ml aliquots of HEPES buffer and
centrifugation at 5006 g for 10 s, through-flow fraction and
wash-fractions were combined and protein concentration was
determined according to the method of Bradford. For visualiza-
tion the depletion efficiency and to control unspecific binding,
bounded albumin and IgG was removed from the resin using
laemmli-buffer (62.5 mM tris-buffer, 2% SDS, 25% glycerol;
pH 7.6) and all samples (pure sample, depleted sample and eluted
albumin- and IgG-fraction) were separated by SDS-PAGE and
stained with Coomassie brilliant blue G-250 (Merck, Darmstadt/
Germany). Effectively depleted biopsy samples were then
characterized by 2D DIGE (Fig. S2).
Sample collection and preparation for proteome analysis
To harvest HL-1 cells for protein isolation, ischemic and non-
ischemic cultures were detached 8 h and 24 h after induction of
ischemia using a cell-scraper. After centrifugation (5006g, 5 min,
20uC) cells were washed twice in 0.56PBS and stored at 280uC.
For cell disruption cell pellet was resuspended in 100 ml
homogenization-buffer (1 mM NaHCO3, 0.2 mM MgCl2,
0.2 mM CaCl2, 1 mM Spermidin, pH 8) including 1% proteinase
inhibitor cocktail (Sigma-Aldrich, Germany) and sonicated on ice
with an ultrasonic processor sonifier (Hielscher GmbH, Stuttgart/
Germany; two cycles of sonification, 30 s each). Cell debris was
removed by centrifugation (10 0006 g, 10 min, 4uC) and the
protein concentration of the supernatant was determined accord-
ing to the method of Bradford. The isolated proteins were stored at
280uC. Biopsy samples were also sonicated as described and
concentrations were sized by Bradford-assay.
150 mg of each sample were precipitated by adding five volumes
of ice-cold acetone for 10 min at 220uC and centrifugation
(13 000 rpm, 4uC, and 15 min). The resulting protein pellet was
air dried, dissolved in 30 ml DIGE labelling-buffer (8 M urea,
30 mM Tris, 4% CHAPS, pH 9) and mixed for 10 min at 20uC.
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Cell lysates were labelled with N-hydroxy-succinimidyl ester-
derivatives of the cyanine dyes Cy2, Cy3 and Cy5 (GE-
Healthcare, Uppsala/Sweden) according to the recommendation
of the supplier and as described earlier [46]. In brief, 1 nM stock
solution of these dyes was diluted 1:5 with dry DMF. If necessary,
the pH of the protein solution was adjusted to pH 8.5 with DIGE-
labelling buffer (pH 9), and then 100 mg of lysate was minimally
labelled with 200 pmol of either Cy3 or Cy5. The labelling
strategy was as follows: the control samples were always labelled
with Cy3, the ischemic samples with Cy5 and for normalization
the same amount of proteins from a pool of all samples was
labelled with Cy2. Labelling reactions were performed on ice in
the dark for 30 min and then quenched by addition of 0.5 mlo f
quenching solution (10 mM lysine; GE Healthcare, Uppsala/
Sweden) to the labelling reaction followed by incubation for
10 min on ice. Differentially labelled samples were mixed prior to
the application to 2D-gel electrophoresis.
IPG-strip rehydration, IEF and 2D-gel electrophoresis
The mixed labelled samples were made up to 400 ml with
DeStreak-rehydration solution (GE-Healthcare, Uppsala/Swe-
den), including 0.5% IPG buffer 3–10 NL and shaken for
10 min at 20uC. To remove unsolved proteins samples were
centrifuged for 30 min, 13 000 rpm at 20uC. The protein
solutions were applied to IPG-strips (18 cm, 3–10 NL, GE
Healthcare) in the rehydration tray and overlaid with 3 ml oil.
One IPG strip was used for each sample set, composed of Cy3
labelled control sample, Cy5 labelled ischemic/ischemic-reperfu-
sion sample and Cy2 labelled pool of all samples. Immobilized
non-linear pH gradient strips were rehydrated with Cy-labelled
samples in the dark at room temperature overnight.
On the next day, each IPG strip was placed in the IEF-chamber
(Ettan IPGphor 3, GE Healthcare). Isoelectric focussing started at
500 V and the voltage was gradually increased to 8000 V within
5 h and kept at 8000 V for at least 10 h at 20uC. The
electrofocussing was finished after a total amount of 90–
100 kVh. Following focussing and washing, strips were equilibrat-
ed on a shaker for 15 min with 2 ml equilibration buffer,
containing 6 M urea, 30% glycerol, 4% SDS, 0.05 M Tris/HCl,
bromophenol blue and 20 mg/ml DTE, followed by additional
incubation for 15 min in the same buffer containing 25 mg/ml
iodacetamide.
Second dimension electrophoresis was performed on a 10%
SDS-PAGE gel. Therefore equilibrated IPG strips were trans-
ferred onto an 18620 cm gel. Strips were covered with 1%
agarose and run at 6 mA per gel at 12uC overnight until the
bromophenol blue dye front just run on the base of the gel. After
fluorescent scan, gels were stained with colloidal Coomassie
brilliant blue G-250 (Merck, Darmstadt/Germany) and dried
between polyethylene films.
Quantitative gel analysis
Gel pictures were scanned using the Ettan DIGE imager II (GE
Healthcare) and analysed in Decodon Delta-2D software vision
3.5 (Decodon, Greifswald/Germany) based on standard position
computing and image fusion functions. After warping the gels
using the all-to-one strategy, a fusion gel was created including all
gels of the experiment. Spot detection was manually edited in the
fusion gel and transferred then to all gel pictures. Normalization of
spot volumes was done to the total protein amount on each gel
(excluding the biggest spots representing ,5% of total intensity) as
described earlier [47]. Mean relative volumes of identical spots in
triplicate gels were calculated and divided by the mean relative
volume of the corresponding spots in the controls, yielding the
expression ratio. Differentially expressed proteins were identified
using the following parameters: expression ratio lowers than 0.5 or
higher than 2 with a p-value of p,0.05, as obtained by the
software’s integrated Student’s t-test.
Analysis of peptides and identification of proteins
In gel digestion. Significantly up- or down-regulated protein
spots were excised from dried colloidal Coomassie stained 2D-
gels using a manual spot picker. Gel pieces were transferred to
Eppendorf tubes and washed twice in a solution of 50%
methanol, 5% acetate and 45% aqua dest.. The digestion was
performed as described elsewhere [48]. In brief, gel pieces were
incubated on a shaker in acetonitrile for 5 min and dried in a
SpeedVac. Samples were reduced in 10 mM dithiotheritol in
10 mM ammonium bicarbonate for 30 min and then alkylated in
100 mM iodacetamide/10 mM ammonium bicarbonate for
30 min at room temperature. Then the gel pieces were washed
twice in acetonitrile and 10 mM ammonium bicarbonate and
vacuum dried. Digestion was done with sequencing grade-
modified trypsin (Sigma-Aldrich) at 37uCo v e r n i g h t .A f t e r
digestion, products were recovered by sequential extraction
with 5 mM ammonium bicarbonate and extraction-buffer (50%
acetonitrile, 44% aqua dest. and 6% of 85% formic acid). Peptide
extracts were vacuum-dried and resuspended in 10 mlo f0 . 1 %
trifluoroacetic acid (TFA).
MALDI-TOF/TOF-MS and nano-LC-ESI-MS analysis.
Digested HL-1 protein samples (0.5 ml) were spotted onto a
MTP AnchorChip TM 600/384 MALDI plate (Bruker
Daltonics, Bremen/Germany) and mixed with 1 mlo fm a t r i x
(2.5 mg/ml a-cyano-4-hydroxy-cinnamic acid dissolved in
acetonitrile/TFA; 50%/0.1%, v/v). The mixture was allowed
to crystallize at room temperature. After washing the spots with
10 mM ammonium phosphate/0.1% TFA, recrystallization-
solution (60% ethanol, 30% acetone, 0.1% TFA) was added
and allowed to dry. MALDI-MS analysis was performed using
the Ultraflex-III (Flex Control and Flex Analysis; Bruker
Daltonics, Bremen/Germany). The instrument was calibrated
using peptide calibration mix II as an external standard in MS
and MS/MS procedure. The peptide calibration mix contained
the following peptides: Angiotensin II, Angiotensin I, Substance
P, Bombesin, ACTH clip 1–17, ACTH clip 18–39, Somatostatin
28 and covered thereby the mass range from 1000–3200 Da.
Human biopsy samples were analysed with ESI-MS. Therefore,
digested samples were desalted and purified using ZipTip strategy
(Millipore; Billerica/USA) and dissolved in ESI-buffer containing
3% acetonitrile and 0.1% formic acid in aqua dest.. Peptides
were separated by reversed-phase nano-LC (LC1100series,
Agilent Technologies, Santa Clara, CA, USA; column: Zorbax
300SB-C18, 3.5 mm, 15060.075 mm; eluent: 0.1% formic acid,
0–60% CAN [49]) and analysed by MS/MS TRAP XTC mass
spectrometer, Agilent Technologies.
Database search. Database search was carried out using the
MS/MS ion search (MASCOT 2.2.1, http://www.matrixscience.
com) against either mouse for in vitro experiment samples or
human for biopsy samples in the NCBInr database using the
following parameters: trypsin digestion, up to one missed cleavage,
fixed modifications: carbamidomethyl (C), and with the following
variable modification: oxidation (M), mass tolerance 100 ppm.
Proteins were specified as clearly identified if the Mowse score was
higher than 55 (MALDI-MS) or 100 (ESI-MS) and at least two
different peptides (p,0.05) were used for identification. Calculated
molecular weight and pI were cross checked with the gel position
of the excised spot. Identified proteins were categorized into
DIGE-Analysis of Ischemic Cardiac In Vitro Model
PLoS ONE | www.plosone.org 12 February 2012 | Volume 7 | Issue 2 | e31669discrete pathways by database research (pubmed) and peer
reviewed journal screening.
Western blot analysis
Equal amounts of protein from control and ischemic/ischemic-
reperfused HL-1 cells, as well as control and diseased human
biopsy samples were applied to 7.5–12% acrylamide gels and
electrophoresed under reducing conditions at 100 V. After
electrophoresis, samples were transferred onto PVDF membranes
using a semi dry system (Bio-Rad). HSP70-specific polyclonal
rabbit antibody and HSP90 specific monoclonal rabbit antibody
(both 1:1000; Cell Signaling Technology, Danvers/USA) for HL-1
cardiomyocytes and human biopsy proteins as well as rabbit
polyclonal anti-PARP antibody (1:1000; BD Pharmingen, USA),
mouse monoclonal-rac1 antibody (1:1000; Abcam, USA), rabbit
polyclonal anti-Connexin-43 (1:1000; Santa Cruz Biotechnology),
rabbit polyclonal-anti calsequestrin (1:1000; Abcam), rabbit
polyclonal anti-beta-tubulin and rabbit polyclonal anti-GAPDH
(both 1:2000; Abcam) for the in vitro HL-1 culture were used for
overnight incubation of PVDF-membranes. The antigens were
detected using peroxidase-conjugated anti mouse- or anti rabbit
antibody (0.08 mg/ml; Jackson ImmunoResearch, Suffolk/UK).
Chemiluminescence signal was measured using Quantity One 4.3
measurement software (Bio-Rad). All measurements were normal-
ized to histon signals using rabbit polyclonal anti histon h3
antibody (1:5000; Abcam, Canada). Biopsy samples were normal-
ized to the total protein amount.
Electrophysiological measurement
For electrophysiological field potential measurements HL-1 cells
were seeded on multielectrode-arrays (MEA) that consists of 60
titan-nitride microelectrodes with a diameter of 30 mm and an
electrode spacing of 200 mm. When the HL-1 monolayer reached
confluence and formed a synchronous beating syncytium, the
MEAs were inserted into a MEA1060-BC field potential amplifier
(Multichannel Systems, Germany) and incubated at 37uC for at
least one hour prior to experiment beginning. To avoid
evaporation of the medium by air-circulation arrays were covered
with a cap. Field potential streams were recorded with 4 kHz
sampling frequency. Signals were recorded for 8 h under ischemic
conditions following revitalization with Claycomb-culture medium
and recording for additionally 16 h. Detection of the electrode
spikes was done offline by a self-developed software written in
MATLAB version 7.01 (The Mathworks, USA).
Statistical analysis
All statistical analyses were performed using GraphPad Prism 5.
All values are expressed as means 6 standard error of mean.
Comparison between two groups was done by a two-tailed
unpaired t-test. Comparison of two or more groups and
parameters were done by 2D-ANOVA and Bonferroni post-hoc
test. Proteins spots were statistical analysed using the Delta 2D
version 3.6 integrated analysis tool incorporates algorithms from
the TIGR Multiple Experiment Viewer (MeV, version 4.0,
tm4.org/mev.html). Differences between two means with
p,0.05 were considered significant, p,0.01 very significant and
p,0.001 extremely significant.
Supporting Information
Figure S1 Experimental protocol and ischemia/reper-
fusion influence to contraction rate of HL-1 cardiomy-
ocytes. Cardiomyocytes were cultivated 4 days in vitro to a
confluent and contractile phenotype, before induction of ischemia.
After 8 h incubation medium exchange was done for revitalization
of cardiomyocytes. Harvesting cells for proteomic and immuno-
cytochemical applications was done before induction of ischemia
(0 h), 8 h after induction of ischemia and 16 h after reperfusion
(24 h). Contraction rate in ischemic and reperfused HL-1
cardiomyocytes was recorded by multielectrode-array based field
potential measurement.
(TIF)
Figure S2 Depletion efficiency of albumin and IgG
removal in human biopsy samples. (A) SDS-PAGE of
biopsy samples before and after albumin and IgG removal using
monoclonal antibody strategy. Lane 1: crude biopsy samples, lane
2: depleted samples, lane 3: albumin fractions. All fractions were
separated on a 12% polyacrylamide gel and stained with
Coomassie brilliant blue. Quantification was done by densitom-
etry. (B) 2D-geleletrophoresis of crude biopsy samples (left) and
depleted samples (right) stained with Coomassie brilliant blue (top
images) and with Cy
TM-dyes using DIGE-strategy (bottom
images). The albumin spot (white sphere) prior depletion disguises
a lot of other spots, which could be detected sensitively after
purification.
(TIF)
Figure S3 Expression profile of analysed DIGE-2D-data
from ischemic HL-1 cardiomyocytes and from biopsy
samples from patients with ischemic cardiomyopathy
via hierarchical cluster analysis. By using an unsupervised
approach comprising all spots the gels were clustered into the
correct groups (n=3).
(TIF)
Table S1 Identified proteins from differentially abun-
dant spots following ischemia in HL-1 cardiomyocytes.
(DOC)
Table S2 Identified proteins from spots of differentially
abundant spots following reperfusion in HL-1 cardio-
myocytes.
(DOC)
Table S3 Westernblot analysis of regulated proteins
following ischemia/ischemia-reperfusion injury in HL-1
cardiomyocytes (% to histone H3).
(DOC)
Table S4 Identified proteins from differentially abun-
dant spots following ischemic cardiomyopathy in male
biopsy samples.
(DOC)
Table S5 Identified proteins from differentially abun-
dant spots following ischemic cardiomyopathy in female
biopsy samples.
(DOC)
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